Y-chromosome loss is frequent in male renal tumors

Franziska Büscheck; Christoph Fraune; Seyedehmina Garmestani; Ronald Simon; Martina Kluth; Claudia Hube-Magg; Kathrin Ketterer; Christian Eichelberg; Doris Höflmayer; Frank Jacobsen; Corinna Wittmer; Waldemar Wilczak; Guido Sauter; Margit Fisch; Till Eichenauer; Michael Rink

doi:10.21037/atm-20-3061

Y-chromosome loss is frequent in male renal tumors

Ann Transl Med. 2021 Feb;9(3):209. doi: 10.21037/atm-20-3061.

Authors

Franziska Büscheck¹, Christoph Fraune¹, Seyedehmina Garmestani¹, Ronald Simon¹, Martina Kluth¹, Claudia Hube-Magg¹, Kathrin Ketterer¹, Christian Eichelberg², Doris Höflmayer¹, Frank Jacobsen¹, Corinna Wittmer¹, Waldemar Wilczak¹, Guido Sauter¹, Margit Fisch³, Till Eichenauer³, Michael Rink³

Affiliations

¹ Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52 D-20246 Hamburg, Germany.
² Clinic for Urology, Krankenhaus St. Josef, Landshuter Straße 65 D-93053 Regensburg, Germany.
³ Department of Urology, University Medical Center Hamburg-Eppendorf, Martinistr. 52 D-20246 Hamburg, Germany.

Abstract

Background: Loss of the Y-chromosome is a common event in different tumor types but its prevalence and clinical relevance in renal cell tumors is still not understood.

Methods: It was the aim of this study to estimate the frequency and clinical relevance of Y-loss in kidney neoplasms. A cohort of 1,252 male renal tumors was analyzed in a tissue microarray format by fluorescence in-situ hybridization (FISH).

Results: Y-loss was found in 47% of tumors. The frequency of this alteration varied markedly between kidney tumor subtypes. Y-loss was most prevalent in papillary renal cell carcinoma (RCC) (77%) followed by chromophobe RCC (60%), oncocytoma (51%), clear cell RCC (39%) and clear cell (tubulo)papillary RCC (19%). Y-loss was linked to higher patient age and smaller tumor size at diagnosis. Mean age (95% CI) was 65 (64-66) years in patients with Y-loss in their tumor compared to 60 (58-61) years in patients without Y-loss (P<0.0001). Significant correlations between Y-loss and tumor phenotype were found only for papillary carcinomas (P=0.002), especially for type 1 (P=0.03).

Conclusions: Y-loss is present in different histologic subtypes of renal neoplasm. The highest frequency is in papillary RCC, where it may represent a potentially relevant prognostic biomarker suggesting favorable disease outcome.

Keywords: Y-loss; fluorescence in-situ hybridization (FISH); prognosis; renal cell neoplasm.